AirSculpt Strengthens Balance Sheet with $10.0 Million Debt Paydown

Rhea-AI Summary

AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has announced a voluntary $10.0 million prepayment of its term loan debt using cash from a recent stock offering. The company successfully completed an offering of 3,634,000 common shares, generating net proceeds of approximately $13.8 million. Following the offering, AirSculpt's total outstanding shares increased to 62,436,670. The company plans to pay the remaining $2.9 million principal on its revolving credit facility by June 16, 2025, which will maintain full availability of $5.0 million. Management stated they don't anticipate needing additional material capital raises this year, assuming stable macroeconomic conditions.

Positive

• Voluntary prepayment of $10.0 million in term loan debt strengthens balance sheet
• Successfully raised $13.8 million through common stock offering
• Full $5.0 million revolving credit facility will be available after final payment
• No anticipated need for additional capital raises in 2025

Negative

• Dilution of existing shareholders through issuance of 3,634,000 new shares
• Use of significant portion of cash reserves for debt repayment

MIAMI BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced the voluntary prepayment of $10.0 million of its outstanding term loan debt using cash on hand, following the successful completion of its offering of 3,634,000 shares of common stock, which generated net proceeds, after estimated expenses, of approximately $13.8 million. The Company noted that with this financing and assuming no significant changes in the current macroeconomic environment, it does not anticipate the need for additional material capital raises this year.

Commenting on the announcement, Yogi Jashnani, Chief Executive Officer, stated: “On the heels of our successful offering of common stock, we are pleased to apply a substantial portion of the proceeds to prepay $10.0 million in our outstanding debt. As a result, we move forward with an improved capital structure and enhanced financial flexibility. This will enable us to implement the strategic priorities that advance our transformation, helping position us to deliver sustained long-term growth in revenue and profitability.”

Following the completion of its offering of common stock, the Company now has 62,436,670 shares of common stock outstanding. Additionally, the Company will have full availability of $5.0 million under its revolving credit facility, after completing the remaining payment of $2.9 million on the outstanding principal on June 16, 2025.    

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Forward-Looking Statements

This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements that relate to our capital structure and liquidity position, our expectations regarding the necessity and timing of future capital raises and financings, our future financial performance, our anticipated growth strategies, anticipated trends in our business, and other information that is not historical information. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements.

Factors that may cause such a difference include, but are not limited to, risks and uncertainties related to our ability to raise capital on commercially reasonable terms, if at all; the risk that any future capital raises or financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in the regulatory, macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest.

The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K.

There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.

Investor Contact:

Allison Malkin
Partner, ICR Inc.
AirSculpt@icrinc.com

FAQ

How much debt did AirSculpt (AIRS) prepay in June 2025?

AirSculpt voluntarily prepaid $10.0 million of its outstanding term loan debt using cash on hand.

How many shares did AirSculpt (AIRS) issue in its 2025 stock offering?

AirSculpt issued 3,634,000 shares of common stock, raising net proceeds of approximately $13.8 million.

What is AirSculpt's (AIRS) total number of outstanding shares after the 2025 offering?

Following the stock offering, AirSculpt has 62,436,670 shares of common stock outstanding.

How much will be available on AirSculpt's (AIRS) revolving credit facility?

AirSculpt will have full availability of $5.0 million under its revolving credit facility after paying the remaining $2.9 million principal.

Will AirSculpt (AIRS) need additional capital raises in 2025?

The company does not anticipate needing additional material capital raises in 2025, assuming stable macroeconomic conditions.